Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $13.6 million.

  • aTYR PHARMA's Non-Current Assets fell 1085.69% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year decrease of 1294.64%. This contributed to the annual value of $14.9 million for FY2024, which is 1576.92% down from last year.
  • According to the latest figures from Q3 2025, aTYR PHARMA's Non-Current Assets is $13.6 million, which was down 1085.69% from $14.0 million recorded in Q2 2025.
  • aTYR PHARMA's 5-year Non-Current Assets high stood at $18.3 million for Q2 2023, and its period low was $1.7 million during Q1 2022.
  • In the last 5 years, aTYR PHARMA's Non-Current Assets had a median value of $14.0 million in 2025 and averaged $11.3 million.
  • In the last 5 years, aTYR PHARMA's Non-Current Assets plummeted by 4458.92% in 2022 and then surged by 94828.21% in 2023.
  • aTYR PHARMA's Non-Current Assets (Quarter) stood at $2.0 million in 2021, then skyrocketed by 657.88% to $14.9 million in 2022, then rose by 18.41% to $17.7 million in 2023, then fell by 15.77% to $14.9 million in 2024, then fell by 8.32% to $13.6 million in 2025.
  • Its Non-Current Assets was $13.6 million in Q3 2025, compared to $14.0 million in Q2 2025 and $14.0 million in Q1 2025.